<DOC>
	<DOCNO>NCT01150045</DOCNO>
	<brief_summary>PURPOSE : This randomized phase III trial study give oxaliplatin , leucovorin calcium , fluorouracil together compare well work give together without celecoxib treat patient stage III colon cancer previously treat surgery . RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin calcium , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Celecoxib may stop growth tumor cell block enzymes need cell growth . It yet know whether give oxaliplatin , leucovorin calcium , fluorouracil effective without celecoxib treat colon cancer .</brief_summary>
	<brief_title>Oxaliplatin , Leucovorin Calcium , Fluorouracil With Without Celecoxib Treating Patients With Stage III Colon Cancer Previously Treated With Surgery</brief_title>
	<detailed_description>OUTLINE : This multicenter study . Patients stratify accord number positive lymph nodes* ( 1-3 v 4 ) concurrent regular low-dose aspirin ( yes v ) . Patients randomize 1 4 treatment arm . Please see `` Arms '' section information . In arm , treatment celecoxib placebo continue 3 year absence disease progression unacceptable toxicity . Blood tissue sample maybe collect biomarker analysis pharmacogenomic study . The primary secondary objective research study describe . Primary objective : 1 . To compare disease-free survival patient stage III colon cancer randomize standard chemotherapy FOLFOX standard chemotherapy FOLFOX 3 year celecoxib 400 mg daily . Secondary objective : 1 . To contribute international prospective pool analysis compare disease-free survival patient stage III colon cancer randomize 6 treatment adjuvant FOLFOX chemotherapy 12 treatment adjuvant FOLFOX chemotherapy . 2 . To compare overall survival patient stage III colon cancer randomize standard chemotherapy ( FOLFOX ) standard chemotherapy ( FOLFOX ) 3 year celecoxib 400 mg daily . 3 . To contribute international prospective pool analysis compare overall survival patient stage III colon cancer randomize 6 treatment adjuvant FOLFOX chemotherapy 12 treatment adjuvant FOLFOX chemotherapy 12 treatment adjuvant FOLFOX chemotherapy . 4 . To assess toxicity celecoxib maintenance adjuvant therapy patient stage III colon cancer . 5 . To assess difference cardiovascular-specific event celecoxib versus placebo population stage III colon cancer survivor . 6 . To evaluate difference toxicity , particularly cumulative peripheral neuropathy , patient treat 6 treatment FOLFOX compare treat 12 treatment FOLFOX . After completion study therapy , patient follow every 6 month 6 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Requirements tumor parameter 1 . Histologically documented adenocarcinoma colon . The gross inferior ( caudad ) margin primary tumor must lie peritoneal reflection ( i.e. , patient rectal cancer eligible ) . Surgeon confirmation entire tumor peritoneal reflection require case important establish tumor rectal colon primary . 2 . Tumors must completely resect . In patient tumor adherent adjacent structure , en bloc R0 resection must document operative report otherwise confirm surgeon . Near positive radial margin exclusion long en bloc resection perform . Positive proximal margin distal margin exclusion . 3 . Node positive disease ( N1 N2 ) designate AJCC version 7 . Either least one pathologically confirm positive lymph node N1C ( define tumor deposit ( ) subserosa , mesentery , nonperitonealized pericolic perirectal tissue without regional lymph node metastasis ) . Patients resect stage IV disease eligible . 4 . No evidence residual involved lymph node disease metastatic disease time registration . 5 . Patients synchronous colon cancer eligible stag stratification base high N stage advance primary tumor . However , patient synchronous colon rectal primary tumor eligible . 2 . NSAID use Patients ineligible plan regular use NSAIDs dose 2 time per week ( average ) aspirin 325 mg least three time per week , average . Lowdose aspirin exceed 100 mg/day permit . Patients agree stop regular NSAIDs high dose aspirin eligible period require . 3 . Patient history 1 . No previous concurrent malignancy , except treat basal cell squamous cell cancer skin , treat situ cervical cancer , treat lobular ductal carcinoma situ one breast , cancer patient diseasefree least 5 year . 2 . No neurosensory neuromotor toxicity ≥ grade 2 time registration . 3 . No known allergy platinum compound . 4 . No prior allergic reaction hypersensitivity sulfonamide , celecoxib NSAIDs . 5 . No history upper gastrointestinal ulceration , upper gastrointestinal bleeding , upper gastrointestinal perforation within past 3 year . Patients ulceration , bleed perforation low bowel exclude . 6 . No symptomatic pulmonary fibrosis interstitial pneumonitis ≥ grade 2 . 7 . No cardiac risk factor include : Uncontrolled high blood pressure ( systolic blood pressure &gt; 150 ) . Unstable angina . History document myocardial infarction cerebrovascular accident . New York Heart Association class III IV heart failure . 4 . Pregancy/nursing status Nonpregnant nursing . Men woman childbearing potential must agree employ adequate contraception duration chemotherapy many 8 week completion chemotherapy due unknown teratogenic effect FOLFOX develop fetus . 5 . Age performance status 1 . ECOG performance status 0 , 1 2 . 2 . Age least 18 year . 6 . Required initial laboratory value 1 . Granulocytes ≥ 1,500/μL 2 . Platelet count ≥ 100,000/μL 3 . Creatinine ≤ 1.5 time upper limit normal ( ULN ) 4 . Total Bilirubin ≤ 1.5 time ULN absence Gilbert 's disease 5 . Direct bilirubin ≤ 1.5 x upper limit normal patient Gilbert 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage III colon cancer</keyword>
</DOC>